Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 6/20 | 0.48 |
| ▸ | S1PR4 | O95977 | 5/20 | 0.48 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.48 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.48 |
| ▸ | LPAR3 | Q9UBY5 | 6/20 | 0.45 |
| ▸ | S1PR5 | Q9H228 | 4/20 | 0.44 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9330077 | 0.77 | CNR1 (0.51) | S1PR1S1PR3S1PR2CNR1 | |
| SCHEMBL7202275 | 0.77 | CNR1 (0.47) | CNR1 | |
| Ammonia Solution, Strong SCHEMBL25175634 | 0.76 | ALOX5 (0.47) | S1PR1S1PR4S1PR3S1PR2S1PR5 | |
| SCHEMBL6052971 | 0.76 | S1PR1 (0.55) | S1PR1S1PR4S1PR3S1PR2LPAR3 | |
| SCHEMBL25456795 | 0.75 | ALOX5 (0.48) | S1PR1S1PR4S1PR3S1PR2 | |
| Ammonia Solution, Strong SCHEMBL25167613 | 0.74 | ALOX5 (0.47) | S1PR1S1PR4S1PR3S1PR2 | |
| SCHEMBL13382757 | 0.72 | S1PR1 (0.62) | S1PR1S1PR4S1PR3S1PR2LPAR3 | |
| SCHEMBL19766701 | 0.72 | PPARA (0.49) | S1PR1 | |
| SCHEMBL10891350 | 0.72 | LPAR3 (0.61) | S1PR1S1PR4S1PR3S1PR2LPAR3 | |
| SCHEMBL7205276 | 0.70 | MMP9 (0.53) | CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11802135-B2 | Lysophosphatidic acid derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-10-31 | — | — | US | disclosed |
| US-11802135-B2 | Lysophosphatidic acid derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-10-31 | — | — | US | disclosed |
| US-20230146210-A1 | NOVEL LYSOPHOSPHATIDIC ACID DERIVATIVE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-05-11 | — | — | US | disclosed |
| US-20230146210-A1 | NOVEL LYSOPHOSPHATIDIC ACID DERIVATIVE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11802135-B2 | Lysophosphatidic acid derivative | LPAR4, LPAR2, LPAR1 | S1PR1 32/4885S1PR4 12/4885S1PR3 27/4885 |
| US-20230146210-A1 | NOVEL LYSOPHOSPHATIDIC ACID DERIVATIVE | LPAR4, LPAR2, LPAR1 | S1PR1 31/4885S1PR4 12/4885S1PR3 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.